Benzinga | Oct 28, 2021 06:12AM EDT

Edgewise Therapeutics Announces Topline Results From The EDG-5506 Phase 1 Multiple Ascending Dose Study In Healthy Volunteers And Doses First Becker Muscular Dystrophy Patients

-- EDG-5506 was generally well tolerated with no serious adverse events observed to date --

-- Pharmacokinetic (PK) data demonstrated robust target engagement with achievement of muscle concentrations well above efficacious levels observed in preclinical disease models --

-- Pharmacodynamic (PD) data demonstrated dose proportionate effect on involuntary twitch inhibition in HVs --

-- Phase 1a single ascending dose/MAD package supports initiation of Phase 2 trials in BMD and Duchenne muscular dystrophy (DMD) in 2022 --

-- Management hosting webcast to discuss findings today at 9:00 a.m. Eastern Time --